This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moon, E. Articles by Lerner, A. Search for Related Content PubMed PubMed Citation Articles by Moon, E. Articles by Lerner, A.

Inhibition of PDE3B Augments PDE4 Inhibitor-induced Apoptosis in a Subset of Patients with Chronic Lymphocytic Leukemia¹

Department of Medicine, Section of Hematology and Oncology, Boston Medical Center, Boston, Massachusetts 02118 [E. M., R. L., R. N., L. W., A. L.]; Department of Pathology, Boston University School of Medicine, Boston, Massachusetts 02118 [A. L.]; and ICOS Corporation, Bothell, Washington 98021 [S. W.]

Purpose: cAMP phosphodiesterase (PDE) 4 is a family of enzymes the inhibition of which induces chronic lymphocytic leukemia (CLL) apoptosis. However, leukemic cells from a subset of CLL patients are relatively resistant to treatment with the PDE4 inhibitor rolipram, particularly when this drug is used in the absence of an adenylate cyclase stimulus such as forskolin. Elevated cAMP levels induce compensatory up-regulation of several cyclic nucleotide PDE families in other model systems. We here examine the hypothesis that CLL cells that survive treatment with rolipram do so as a result of residual PDE activity that is not inhibited by this drug.

Experimental Design: We examined by Western analysis the effect of rolipram treatment on CLL expression of PDE3B, PDE4A, PDE4B, PDE4D, and PDE7A. We also examined the ability of rolipram (PDE4 inhibitor) or cilostamide (PDE3 inhibitor), alone or together, to induce apoptosis or elevate cyclic AMP in leukemic cells from patients with CLL.

Results: Rolipram increased levels of PDE4B and, to a variable extent, PDE4D. When combined with forskolin, rolipram also increased levels of a second family of PDEs, PDE3B. Addition of the specific PDE3 inhibitor, cilostamide, modestly augmented rolipram-induced apoptosis in five of seven "rolipram-resistant" CLL samples.

Conclusions: Although this work confirms that PDE4 appears to be the most important PDE target for induction of apoptosis in CLL, combination therapy with PDE3 and PDE4 inhibitors or use of dual-selective drugs may be of benefit in a subset of relatively PDE4-inhibitor resistant CLL patients.

This article has been cited by other articles:

				P. Klener, M. Szynal, Y. Cleuter, M. Merimi, H. Duvillier, F. Lallemand, C. Bagnis, P. Griebel, C. Sotiriou, A. Burny, et al. Insights into Gene Expression Changes Impacting B-Cell Transformation: Cross-Species Microarray Analysis of Bovine Leukemia Virus Tax-Responsive Genes in Ovine B Cells J. Virol., February 15, 2006; 80(4): 1922 - 1938. [Abstract] [Full Text] [PDF]

				P. B. Snyder, J. M. Esselstyn, K. Loughney, S. L. Wolda, and V. A. Florio The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis J. Lipid Res., March 1, 2005; 46(3): 494 - 503. [Abstract] [Full Text] [PDF]

				S. Tiwari, K. Felekkis, E.-Y. Moon, A. Flies, D. H. Sherr, and A. Lerner Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis Blood, April 1, 2004; 103(7): 2661 - 2667. [Abstract] [Full Text] [PDF]

				G. Ghannam, A. Takeda, T. Camarata, M. A. Moore, A. Viale, and N. R. Yaseen The Oncogene Nup98-HOXA9 Induces Gene Transcription in Myeloid Cells J. Biol. Chem., January 9, 2004; 279(2): 866 - 875. [Abstract] [Full Text] [PDF]

				E.-Y. Moon and A. Lerner PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A Blood, May 15, 2003; 101(10): 4122 - 4130. [Abstract] [Full Text] [PDF]

				M. Sarfati, V. Mateo, S. Baudet, M. Rubio, C. Fernandez, F. Davi, J.-L. Binet, J. Delic, and H. Merle-Beral Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells Blood, January 1, 2003; 101(1): 265 - 269. [Abstract] [Full Text] [PDF]